Zentalis Pharmaceuticals Llc (ZNTL) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.47
• Market Cap: $159.93M
• EPS: $-2.08
• 52-Week High: $3.95
• 52-Week Low: $1.01

Market Sentiment

Zentalis Pharmaceuticals Llc currently has a Neutral sentiment score of -0.03.

About Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, focused on developing innovative small molecule therapies for cancer treatment through precision medicine. The company is advancing a promising pipeline that targets critical pathways involved in tumor growth and resistance, addressing significant unmet medical needs in oncology. Zentalis's strategic approach and commitment to innovation position it as a potential leader in the biopharmaceu...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Zentalis Pharmaceuticals Llc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ZNTL pay dividends?

Zentalis Pharmaceuticals Llc (ZNTL) does not currently pay a regular dividend.

What is ZNTL's market cap?

Zentalis Pharmaceuticals Llc (ZNTL) has a market capitalization of $159.93M with a current stock price of $2.47.